Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
News|Articles|August 4, 2026
FDA updates in urology: July 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from July 2026.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! This month’s regulatory news featured several practice-changing developments across bladder and prostate cancer, with key approvals in muscle-invasive
Related to this article
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Eugene Cone, MD, discusses the impact of ongoing BCG supply challenges and the potential role of alternative and recombinant strains for NMIBC care.
Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.
Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.
All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.
Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.
John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.
Advertisement
Advertisement